

THE CBSA FOCUS FALL 2009



A QUARTERLY LOOK AT COLORADO'S MEDICAL DEVICE AND BIOTECHNOLOGY INDUSTRIES

The First Annual Rocky Mountain Investor Conference

A little over one year ago, Governor Ritter began a quest on behalf of the bioscience industry within the Rocky Mountain region. At the national Biotechnology Industry Organization (BIO) Conference, Governor Ritter was able to garner support to allow the Colorado BioScience Association to launch the region's first and only life science investor conference, the Rocky Mountain Life Science Investor Conference (RMLIC) will come to fruition on September 17th.

Over the last few years, Colorado and the region has been gaining more attention among the investment community and the RMLIC will allow companies the chance to showcase their research while also allowing investors the chance to see the incredible opportunities that lie within the Rockies.

"Given the explosive growth of biotech and medical device companies in the region in the last six years, this conference will provide an excellent opportunity for leading companies to describe their work to interested investors," said Chris Christoffersen, Partner with Morgenthaler Ventures. "Both are likely to be surprised at opportunities for mutual interest."

Not only will the conference allow 30 companies to present their technologies but it will also offer a partnering system for both presenting companies and attendees. The partnering system will allow you to see who is attending the conference and provide a portal for all attendees to contact one another via email and request one-on-one private meetings during the event.

"Partnering and networking are essential components to a bioscience company," said John Collar, President and CEO of CBSA. "The partnering system at the Rocky Mountain Life Science Investor Conference allows individuals to easily hold meetings with interested parties and begin that networking and relationship building."

While the conference focuses on the partnering and company presentations, there will also be two discussion panels and two keynote addresses offered for attendees to participate in. The conference will commence with a breakfast keynote presentation by Roy Davis, President of Johnson & Johnson Corporate Development & Corporate Venturing, who will lend his insight behind the world of biosciences and his expectations for the bioscience industry. He will also delve into the world of partnerships and the importance of

IN THIS ISSUE

The Rocky Mountain Investor Conference

The 2009 Summer Externship Program

Letter from John Collar

The Fitz Bulletin Board

CBSA SPONSORS

Platinum

- » Cooley Godward Kronish
- » Colorado State University
- » University of Colorado Technology Transfer Office

Gold

- » Colorado Science + Technology Park at Fitzsimons
- » Merck & Co., Inc.

Silver

- » Amgen
- » CaridianBCT
- » Denver Museum of Nature & Science
- » Ernst & Young
- » Fitzsimons Redevelopment Authority
- » Pfizer

Bronze

- » Baxa Corporation
- » Dorsey & Whitney
- » Fairfield & Woods
- » Hogan & Hartson
- » Holland & Hart
- » Johnson & Johnson
- » OSI Pharmaceuticals
- » PhRMA
- » Polsinelli Shughart
- » We Work for Health

attending conferences and networking to build relationships and collaboration within the industry.

Over the last year, the state of Colorado has been anticipating the return of Dr. Tom Cech to the University of Colorado Boulder and the implementation of the new Colorado Initiative for Molecular Biology (CIMB). Dr. Cech will provide the luncheon keynote presentation during the RMILC and give the audience a preview into his research and what the future holds. The CIMB will be opening its doors in December of 2011, and during Dr. Cech's presentation he will be able to discuss the collaboration and innovation that will generate from this unique project.

In addition to the two keynote presentations, the RMLIC will showcase two panel discussions during the day. The first panel, moderated by Dr. Patrick Mahaffy, President and CEO of Clovis Oncology, will discuss business development inside the bioscience industry and what peaks the interest of the large biotech, pharmaceutical and medical device companies.

The second panel will consist of venture capital leaders from across the nation to provide advice and lessons learned to the participants at the Conference. The Venture Capital Panel will be moderated by Chris Christoffersen, Partner Morgenthaler Ventures and include Jamie Topper, MD, Partner, Frazier Healthcare Ventures; Steven Weinstein, Managing Director, Novartis Venture Fund; and Jim Glasheen, Ph.D., Partner, Technology Partners.

"This is an opportunity that companies in the region cannot let pass them by," said John Collar. "Having the ability to connect one-on-one with a group of investors and business development professionals right in your own backyard is priceless, and we are pleased to bring this to the companies within Colorado and the Rocky Mountain Region."

The 2009 Summer Externship

A local high school biology teacher is learning the ropes at a Boulder biotechnology company this summer, as part of a six-week paid externship program launched by the Colorado BioScience Association. Tammy Hearty, a Fairview High School biology teacher, is the second teacher to take part in the CBSA's externship program and has spent part of her summer at OSI Pharmaceuticals in Boulder.

"We were thrilled to have Tammy involved in the science teacher externship program this summer," explains John Collar, President and CEO of CBSA. "This program is a great avenue to assist teachers with their lesson plans and understanding of the inner workings of a bioscience company. With Tammy's enthusiasm and excitement for science, she was the perfect candidate and will be able to bring everything she learned back to her students. She has also offered to help us create a better program in the future by creating different objectives and goals for the extern."

Hearty's experience at OSI includes investigating a preservative on a tissue sample to see if the preservative will keep the tissue's DNA intact, this will show whether the use of the preservative will allow the

UPCOMING EVENTS

[Rocky Mountain
Investor Conference](#)

[BioWest 2009](#)

DNA to sequence correctly. So far, this hypothesis is not working as well as hoped, but as many research scientists can attest this is an expected turn of events.

"I try to be so careful and still things go wrong," explains Hearty. "I think it helps when you start to see the big picture and know what direction you are heading. It seems like a great deal of fun and adventure at first, but there's a significant learning curve and I get a 'brain-full' of new information every single day."

Hearty explains that the externship experience has given her more perspective on what companies are doing with science and biology, and this new perspective will help her engage and interest students in science. "What I'm learning here can transfer to my students, and my understanding and love of science can translate that enthusiasm onto them. I'm beginning to think about how lab techniques are fun and hands on experiences where you are constantly doing something, and then figuring out how I can do more of this with my students. Enjoying the science and applying the science."

Letter From John Collar

Being a part of the Colorado BioScience Association over these last nine months has been quite an experience, and I am honored to call the CBSA home. Learning more about each of our member companies and individuals has been a privilege, and I hope to continue learning more about each of you as the next months pass by.

While the CBSA is never short on things to do, this Fall and Winter we are expecting a full schedule. The inaugural Rocky Mountain Life Science Investor Conference will be here before we know it with over 30 investors and business development professionals company to the city of Denver. This is a great opportunity for our bioscience companies here in Colorado and in the region. This gives companies and researchers the ability to present to interested investors and for everyone to partner together during one-on-one meetings set up through a partnering system. This event has been a long time in the making, and we are excited to finally see it come to fruition on September 17th.

Another anticipated event is the BioWest Conference, and this year's conference will not disappoint. Once again BioWest is expecting over 700 attendees with nearly 60 exhibitors showcasing their products and services. The schedule is also jam packed with nationally acclaimed speakers, an investor forum and an inside look at Colorado's economy. The Annual Awards Dinner will close out the conference, so be sure to get a seat for this program and see who receives recognition this year!

While these two conferences will keep things busy, the CBSA will continue its normal programming, prepare for the 2010 legislative session and engage in education initiatives that focus on improving the science and math curriculum in our schools. As I said before, this Fall and Winter are going to remain busy for the CBSA but we are all excited to see where it takes us. Thank you again for allowing me to represent the bioscience community in our state, and I am looking

forward to another successful nine months.



The Fitzsimons Life Science District Announces *The Fitz Bulletin Board* and the 2009 BioSymposium on Pulmonary Disease

The partners of the Fitzsimons Life Science District in Aurora, Colorado, have launched a new website and blog. The website was redesigned to better serve more focused content to the tenants, faculty and staff in the District and adjacent University of Colorado Denver Anschutz Medical Campus. Repositioned as a resource, the website includes a blog called the Fitz Bulletin Board, in an ambitious attempt to get bioscience professionals talking about their experiences in funding, challenges and successes in the conception and implementation of their entrepreneurial ventures. It is also a posting ground for bio industry events in and around the District as well as a centralized news feed for industry articles as they pertain to Fitzsimons. It is intended to be a place for the University of Colorado Denver, The Children's Hospital, The University Hospital, Colorado Bioscience Association, Veterans Affairs Hospital and bioscience industry, all to join in a conversation. It will highlight research, forums, panels and discussion groups, events and ideas to better cultivate a healthy bioscience community within the District and in Colorado.

Visit us at www.fitzscience.com and click on the Fitz Bulletin Board.

In addition to laying this community foundation in the digital space, the Fitzsimons Life Science District has partnered with the University of Colorado Denver School of Medicine to host a research-centric forum and conference for health science professionals to discuss research towards pulmonary health. The 2009 BioSymposium on Pulmonary Disease will take place the day before the Rocky Mountain Life Science Investors Conference on September 16, 2009. It will be held in Research Complex 2 on the UCD Anschutz Medical Campus, and will feature thought leaders in pulmonary research from the University of Colorado Denver, National Jewish Health, and industry. The keynote will feature Eric Olson, MD, from the University of Texas Southwestern Medical Center at Dallas, speaking on The Treatment of Pulmonary Artery Hypertension.

For registration information and details please visit the website at www.uchsc.edu/som/biosymposium. To view the full list of panelist and speakers, and to stay abreast to conference updates, visit the www.bulletinboard.fitzscience.com and click on 2009 BioSymposium.

www.CoBioScience.com